CCLA Investment Management Has $112.94 Million Stake in Avantor, Inc. (NYSE:AVTR)

CCLA Investment Management boosted its stake in shares of Avantor, Inc. (NYSE:AVTR - Free Report) by 4.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,357,703 shares of the company's stock after purchasing an additional 229,199 shares during the period. Avantor accounts for about 1.8% of CCLA Investment Management's investment portfolio, making the stock its 29th biggest holding. CCLA Investment Management owned 0.79% of Avantor worth $112,940,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. State Street Corp lifted its position in shares of Avantor by 58.0% in the third quarter. State Street Corp now owns 22,368,244 shares of the company's stock valued at $578,666,000 after buying an additional 8,206,695 shares during the last quarter. 1832 Asset Management L.P. lifted its position in shares of Avantor by 1,634.9% in the second quarter. 1832 Asset Management L.P. now owns 8,530,118 shares of the company's stock valued at $180,839,000 after buying an additional 8,038,451 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Avantor by 653.0% in the third quarter. The Manufacturers Life Insurance Company now owns 6,174,736 shares of the company's stock valued at $159,740,000 after buying an additional 5,354,678 shares during the last quarter. FMR LLC lifted its position in shares of Avantor by 557.2% in the third quarter. FMR LLC now owns 4,675,283 shares of the company's stock valued at $120,950,000 after buying an additional 3,963,912 shares during the last quarter. Finally, Sound Shore Management Inc. CT acquired a new stake in shares of Avantor in the second quarter valued at approximately $76,412,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Avantor Price Performance

Shares of AVTR traded up $0.10 during midday trading on Wednesday, hitting $21.82. The company's stock had a trading volume of 7,224,642 shares, compared to its average volume of 4,361,827. Avantor, Inc. has a one year low of $19.59 and a one year high of $28.00. The company's fifty day simple moving average is $21.49 and its two-hundred day simple moving average is $23.36. The company has a quick ratio of 1.06, a current ratio of 1.54 and a debt-to-equity ratio of 0.84. The stock has a market capitalization of $14.85 billion, a price-to-earnings ratio of 47.43, a price-to-earnings-growth ratio of 2.75 and a beta of 1.28.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on AVTR. Robert W. Baird lowered their target price on Avantor from $27.00 to $26.00 and set an "outperform" rating on the stock in a research note on Monday, October 28th. Wells Fargo & Company lowered their target price on Avantor from $30.00 to $28.00 and set an "overweight" rating on the stock in a research note on Monday, October 28th. Royal Bank of Canada reiterated an "outperform" rating and set a $34.00 target price on shares of Avantor in a research note on Thursday, September 26th. UBS Group lowered their target price on Avantor from $30.00 to $29.00 and set a "buy" rating on the stock in a research note on Tuesday, October 8th. Finally, Barclays lowered their target price on Avantor from $28.00 to $25.00 and set an "overweight" rating on the stock in a research note on Friday, October 25th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Avantor has a consensus rating of "Moderate Buy" and an average target price of $27.69.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.